← Leaderboards
Xuefang Cao
Roswell Park Cancer Institute Corp
$8,586,764
Attributed
$8,586,764
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,586,764 · 8
By mechanism
R01$7,293,742 · 3
R21$862,859 · 2
P30$430,163 · 3
Top collaborators
No co-investigators on record.
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Protul Shrikant$4,542,208
- Barbara Todaro$744,325
- Lara Sucheston-Campbell$2,575,366
- Theresa E Hahn$4,613,853
- Sean Colligan$89,295
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsImmuneSignal TransductionInfectionT-LymphocyteAllogenicClinical TrialsMouse ModelPublicationsInnovationOrganMalignant NeoplasmsBaseCollaborationsImmune System DiseasesFlow CytometryMediatingPathogenesisNovel TherapeuticsLeadClinically RelevantAffectGraft Vs Host DiseaseDesign
Grant awards (25)
Beta-2 adrenergic signaling in immune homeostasis and reconstitution$766,025
R01 · FY2025 · HL · contact PI
CD27-mediated immune suppression by HSPCs, innate immune cells or non-hematopoietic cells$427,625
R21 · FY2025 · AI · contact PI
Tumor Immunology and Immunotherapy Program$128,751
P30 · FY2025 · CA · contact PI
Beta-2 adrenergic signaling in immune homeostasis and reconstitution$750,705
R01 · FY2024 · HL · contact PI
Tumor Immunology and Immunotherapy Program$50,965
P30 · FY2024 · CA · contact PI
Beta-2 adrenergic signaling in immune homeostasis and reconstitution$766,025
R01 · FY2023 · HL · contact PI
Tumor Immunology and Immunotherapy Program$50,965
P30 · FY2023 · CA · contact PI
Beta-2 adrenergic signaling in immune homeostasis and reconstitution$766,025
R01 · FY2022 · HL · contact PI
Tumor Immunology and Immunotherapy Program$50,965
P30 · FY2022 · CA · contact PI
CD27/CD70 mediated negative regulation of inflammatory T cell responses$586,090
R01 · FY2021 · HL · contact PI
Tumor Immunology and Immunotherapy Program$50,965
P30 · FY2021 · CA · contact PI
CD27/CD70 mediated negative regulation of inflammatory T cell responses$586,090
R01 · FY2020 · HL · contact PI
Tumor Immunology and Immunotherapy (TII)$48,776
P30 · FY2020 · CA · contact PI
CD27/CD70 mediated negative regulation of inflammatory T cell responses$586,090
R01 · FY2019 · HL · contact PI
Targeting Granzyme B to Separate GVH from GVL Responses$342,815
R01 · FY2019 · CA · contact PI
Tumor Immunology and Immunotherapy (TII)$48,776
P30 · FY2019 · CA · contact PI
CD27/CD70 mediated negative regulation of inflammatory T cell responses$586,090
R01 · FY2018 · HL · contact PI
Targeting Granzyme B to Separate GVH from GVL Responses$353,419
R01 · FY2018 · CA · contact PI
Targeting Granzyme B to Separate GVH from GVL Responses$241,256
R01 · FY2017 · CA · contact PI
Targeting Granzyme B to Separate GVH from GVL Responses$160,200
R01 · FY2017 · CA · contact PI
Targeting Beta-Adrenergic Signaling to Control GVH and GVL Responses$115,322
R21 · FY2017 · CA · contact PI
Targeting Beta-Adrenergic Signaling to Control GVH and GVL Responses$74,012
R21 · FY2017 · CA · contact PI
Targeting Granzyme B to Separate GVH from GVL Responses$401,456
R01 · FY2016 · CA · contact PI
Targeting Beta-Adrenergic Signaling to Control GVH and GVL Responses$245,900
R21 · FY2016 · CA · contact PI
Targeting Granzyme B to Separate GVH from GVL Responses$401,456
R01 · FY2015 · CA · contact PI